Total Payments
$595,523
2024 Payments
$129,131
Companies
41
Transactions
1,849
Medicare Patients
2,707
Medicare Billing
$335,495
Payment Breakdown by Category
Other$474,831 (79.7%)
Travel$58,334 (9.8%)
Food & Beverage$37,050 (6.2%)
Consulting$25,233 (4.2%)
Education$76.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $444,161 | 192 | 74.6% |
| Travel and Lodging | $58,334 | 284 | 9.8% |
| Food and Beverage | $37,050 | 1,349 | 6.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,800 | 10 | 4.5% |
| Consulting Fee | $25,233 | 11 | 4.2% |
| Honoraria | $3,870 | 1 | 0.6% |
| Education | $76.09 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $119,430 | 547 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $112,889 | 124 | $0 (2024) |
| Gilead Sciences, Inc. | $96,696 | 185 | $0 (2024) |
| Janssen Biotech, Inc. | $77,442 | 151 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $45,728 | 77 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30,499 | 124 | $0 (2024) |
| Merck Sharp & Dohme LLC | $28,177 | 61 | $0 (2023) |
| Synergy Pharmaceuticals Inc | $22,745 | 67 | $0 (2018) |
| Madrigal Pharmaceuticals | $16,658 | 23 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $14,889 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $129,131 | 341 | Janssen Biotech, Inc. ($50,135) |
| 2023 | $40,361 | 231 | Janssen Biotech, Inc. ($26,594) |
| 2022 | $69,174 | 251 | Janssen Scientific Affairs, LLC ($26,466) |
| 2021 | $50,137 | 187 | AbbVie Inc. ($19,690) |
| 2020 | $34,180 | 105 | AbbVie Inc. ($14,596) |
| 2019 | $90,681 | 220 | AbbVie, Inc. ($32,793) |
| 2018 | $97,296 | 268 | AbbVie, Inc. ($26,044) |
| 2017 | $84,562 | 246 | Janssen Scientific Affairs, LLC ($23,732) |
All Payment Transactions
1,849 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Gastroenterology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.55 | General |
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $19.41 | General |
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $174.80 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $146.20 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $107.20 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,903.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $85.98 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $53.60 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $188.77 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $97.26 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $3.79 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $65.66 | General |
| Category: Immunology | ||||||
| 11/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $9.30 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 574 | 624 | $649,730 | $69,045 |
| 2022 | 14 | 625 | 693 | $688,385 | $80,208 |
| 2021 | 18 | 809 | 899 | $816,920 | $106,875 |
| 2020 | 14 | 699 | 754 | $644,361 | $79,367 |
Total Patients
2,707
Total Services
2,970
Medicare Billing
$335,495
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 73 | 74 | $143,930 | $15,253 | 10.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 56 | $15,400 | $7,426 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 79 | $15,800 | $7,261 | 46.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 36 | 36 | $63,360 | $6,526 | 10.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 72 | 72 | $132,840 | $6,205 | 4.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 86 | 89 | $116,590 | $5,483 | 4.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 30 | 31 | $54,560 | $4,283 | 7.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 64 | $8,960 | $3,819 | 42.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 18 | 18 | $31,680 | $3,315 | 10.5% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 20 | 23 | $31,050 | $2,626 | 8.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $5,355 | $2,368 | 44.2% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 13 | $23,725 | $2,233 | 9.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 36 | $4,680 | $2,208 | 47.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 12 | 12 | $1,800 | $39.50 | 2.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 68 | 68 | $132,260 | $14,212 | 10.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 60 | 61 | $16,775 | $9,785 | 58.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 68 | 69 | $121,440 | $9,457 | 7.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 103 | $20,600 | $9,184 | 44.6% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 11 | 11 | $16,500 | $7,314 | 44.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 115 | 119 | $155,890 | $6,790 | 4.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 65 | 65 | $119,925 | $6,276 | 5.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 72 | $10,080 | $4,596 | 45.6% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 20 | 27 | $36,450 | $3,328 | 9.1% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 11 | 12 | $22,200 | $2,481 | 11.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $5,610 | $2,336 | 41.6% |
About Dr. Robert Bierwirth, M.D
Dr. Robert Bierwirth, M.D is a Hepatology healthcare provider based in Cranston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1053517565.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Bierwirth, M.D has received a total of $595,523 in payments from pharmaceutical and medical device companies, with $129,131 received in 2024. These payments were reported across 1,849 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($444,161).
As a Medicare-enrolled provider, Bierwirth has provided services to 2,707 Medicare beneficiaries, totaling 2,970 services with total Medicare billing of $335,495. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location Cranston, RI
- Active Since 06/22/2007
- Last Updated 10/15/2025
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1053517565
Products in Payments
- STELARA (Biological) $141,071
- Epclusa (Drug) $67,952
- VOQUEZNA (Drug) $45,728
- TREMFYA (Drug) $42,327
- Mavyret (Drug) $32,379
- Trulance (Drug) $22,745
- MAVYRET (Drug) $19,606
- Creon (Drug) $17,566
- REZDIFFRA (Drug) $16,520
- ZEPOSIA (Drug) $15,875
- TRULANCE (Drug) $13,852
- CREON (Drug) $13,556
- LINZESS (Drug) $11,649
- XIFAXAN (Drug) $9,901
- ZEPATIER (Drug) $9,807
- RELISTOR (Drug) $7,083
- SIMPONI (Biological) $6,750
- Viekira (Drug) $6,649
- MOTEGRITY (Drug) $6,411
- Vosevi (Drug) $4,615
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.